ArticleThe Journal of infectious diseases2025
The Current and Future Burden of Long COVID in the United States.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of Exercise-Based Pulmonary Rehabilitation in Patients with Long COVID: A Systematic Review and Meta-Analysis.Advances in respiratory medicine · 2026Pooled it
- The impact of long COVID on physical and cardiorespiratory parameters: A systematic review.PloS one · 2025Pooled it
- The securitization of global slow-onset risks/threats: long COVID, a case study.Globalization and health · 2026Article
- Article
- Safety, feasibility, and exploratory biomarker findings of bone marrow-derived mesenchymal stromal cells in hospitalized severe COVID-19: a phase I/II randomized trial.Journal of thoracic disease · 2026Article
- COVID-19 Is Airborne AIDS: Provocative Oversimplification, Emerging Science, or Something in Between?AJPM focus · 2026Review
- Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study.Infectious diseases and therapy · 2026Article
- Socioeconomic value of adult respiratory vaccination in the United States: a benefit-cost analysis.Health affairs scholar · 2026Article
- Prevalence and Associations of Medical Expenditure Panel Survey-Defined Long COVID Among Adults: Cross-Sectional Study.JMIR formative research · 2026Article
- Barriers to Long COVID Care in the U.S.: An Application of Levesque et al.'s Access Framework.Health care analysis : HCA : journal of health philosophy and policy · 2026Article
- Transcutaneous Auricular Vagus Nerve Stimulation for Post-COVID-19 Condition: A Systematic Review and Critical Appraisal of Clinical Evidence.Journal of clinical medicine · 2026Review
- Symptom Trajectories and Long-Term Sequelae of COVID-19: A Matched Case-Control Study with Population-Based Controls.Journal of clinical medicine · 2026Article
- Plasma Extracellular Vesicle Surface Marker Profiling Reveals Immune Cell-Associated Mitochondrial Membrane Potential Alterations in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.Open forum infectious diseases · 2026Article
- Longitudinal study of genome-wide DNA methylation in individuals with and without post-acute symptoms following SARS-CoV-2 infection.Epigenomics · 2026Article
- Co-Culture Systems to Study Epithelial-Immune Interactions During SARS-CoV-2 Infection.Current protocols · 2026Article
- Long COVID disability burden in US adults.Communications medicine · 2026Article
- Informing the Value of "Boosting" Immunocompetent Adults based on Immune Responses Among US Service Members to SARS-CoV-2 Variants in Late 2024.Open forum infectious diseases · 2026Article
- Work ability trajectories and sick leave in individuals with post COVID-19 condition: 3-year follow-up of a population-based cohort.The Lancet regional health. Europe · 2026Article
- Family history of cancer as a risk factor for Long COVID among United States adults.Cancer causes & control : CCC · 2026Article
- Excess primary healthcare consultations in Norway in 2024 compared to pre-COVID-19-pandemic baseline trends.Archives of public health = Archives belges de sante publique · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
Abstract
backgroundLong coronavirus disease (COVID), which affects an estimated 44.69-48.04 million people in the United States, is an ongoing public health concern that will persist as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread.
methodsWe developed a computational simulation model representing the clinical course, health effects, and associated costs of a person with long COVID.
resultsSimulations show that the average total cost of a long COVID case can range from $5084-$11 646 (assuming symptoms only last 1 year) with 92.5%-95.2% of these costs being productivity losses. Therefore, the current number of long COVID cases could cost society at least $2.01-$6.56 billion, employers at least $1.99-$6.49 billion in productivity losses, and third-party payers $21.0-$68.5 million annually (6%-20% probability of developing long COVID). These cases would accrue 35 808-121 259 quality-adjusted life-years (QALYs) lost and 13 484-45 468 disability-adjusted life-years (DALYs) and would rise as COVID-19 incidence increases.
conclusionsThe current health and economic burden of long COVID may already exceed that of a number of other chronic diseases and will continue to grow each year as COVID-19 cases increase. This could be a significant drain on businesses, third-party payers, the healthcare system, and society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.